A federal judge has allowed a major antitrust case to move forward against Zelis Healthcare and five of the largest US health insurers, rejecting an effort to shut it down at the pleading stage.
The US District Court for the District of Massachusetts denied a joint motion to dismiss filed by Zelis Healthcare and commercial payer defendants Aetna, The Cigna Group, Elevance Health Companies, Humana, and UnitedHealth Group.
The suit accuses the companies of working together to suppress payments to providers for out-of-network care, according to Insurance Business magazine.
The case centers on Zelis, a healthcare technology company offering network management, claims integrity, and payment services to insurers.
The plaintiffs are providers from several states, including a California medical group with about 100 doctors and healthcare professionals, dental practices in Kansas and Wisconsin, a solo otolaryngologist in New Jersey, a chiropractic practice in California, and another consolidated plaintiff.
Together, they claim Zelis and the insurers built a system that pushed reimbursements down across out-of-network claims.
According to the complaint, the scheme relied on two Zelis repricing products. One, Established Reimbursement Solution, generates a fee schedule based on market payment rates.
The providers argue it leans on in-network rate data, which makes it a distorted benchmark for out-of-network claims and pulls payments lower.
The other, Reference Based Pricing, sets reimbursement at fixed levels. Insurers used both tools to reprice claims and offer reduced payments.
The providers say the process leaves them boxed in. They can accept the lower amount, try negotiating with Zelis in what they describe as a lopsided process, or appeal and usually get nowhere.
One plaintiff, Pacific Inpatient Medical Group, said a claim it submitted was repriced at a discount of more than 88%.
Zelis allegedly takes a percentage of the savings, meaning it earns money from the spread between the billed charge and the final payment.
The complaint says the practice has cut some providers’ out-of-network revenue by 50% or more. Some, according to the filing, have had to consider new business arrangements or shutting down altogether. The plaintiffs also argue patients are not seeing any upside, since premiums kept rising even as provider payments fell.
The defendants attacked the case from several angles, including standing and market definition. On standing, they argued the court should look at each plaintiff and each claim one by one.
The judge disagreed. Because all six plaintiffs brought a single antitrust claim tied to the same alleged conduct and injury, the case survives so long as at least one plaintiff has standing.
The insurers also said the repricing tools did not directly cause the providers’ injuries because providers were free to negotiate better rates or bill patients for the difference. The court did not buy it.
The complaint says providers are effectively unable to negotiate and are barred from balance billing patients. At this stage, the judge said those allegations must be accepted as true.
The defendants also argued the providers had not suffered the sort of injury antitrust law is meant to address. Their position was that lower healthcare costs benefit consumers.
The court rejected that framing and pointed to established precedent holding that suppliers forced to accept artificially depressed prices by a group of strong buyers may claim antitrust injury, even when consumers do not feel direct harm.
According to the court, the law protects competition, not coordinated price suppression dressed up as efficiency.
The conspiracy allegations follow two paths. First, the plaintiffs assert a horizontal conspiracy, claiming Zelis and the insurers compete in the market for out-of-network services and agreed to fix prices. The defendants said Zelis is only a technology vendor, not a competitor.
The court said the complaint goes further than that. It alleges Zelis itself purchases out-of-network healthcare services, which places it in the same market as the insurers.
That point mattered. The court distinguished the case from the MultiPlan litigation in Illinois, where the horizontal conspiracy theory ran into trouble because there were no similar allegations that MultiPlan bought out-of-network services.
The second theory is hub-and-spoke conspiracy. Under that view, Zelis sits at the center and the insurers form the spokes.
The court said the plaintiffs pleaded enough circumstantial evidence to keep that theory alive, including parallel adoption of Zelis tools by competing insurers, sharing of competitively sensitive claims data through Zelis, and the idea that one insurer acting alone would risk losing subscribers if providers stopped taking its patients.
The defendants also challenged the market definition. They argued out-of-network services were too broad a product market and that a nationwide geographic market made no sense.
The court said both definitions were plausible for now. Market definition, the judge wrote, is fact intensive and usually not something courts should resolve on a motion to dismiss.
Humana raised a separate point. It said the complaint itself acknowledges the company stopped selling the commercial health insurance products at issue in 2024.
The court said that does not shield Humana from potential liability for alleged conduct before then. The plaintiffs say the conspiracy began on or around June 13, 2016.
The court also issued a separate ruling on March 4, 2026. In that decision, it granted motions by Aetna, UnitedHealth, and Elevance to compel arbitration against certain plaintiffs and stayed those specific claims.
The case now moves into discovery. That is where the central fight gets sharper: whether Zelis functioned as a cost-management service or as the mechanism of a broader price-fixing arrangement. For insurers, the risk goes well beyond one lawsuit.
If the plaintiffs prove a conspiracy, the ruling could force a hard reset in how out-of-network repricing works across the commercial health insurance market.
